Novo Nordisk, Zepbound and Weight Loss
Digest more
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
1d
Best Life on MSNWeight-Loss Drugs Could Slash Cancer Risk by 41%—Here’s Who BenefitsParticipants in a new study who used GLP-1 drugs had a much lower cancer risk than those who had bariatric surgery.
Hosted on MSN1d
Do Medicare, Medicaid cover weight loss drugs? It dependsWellcare, which offers Medicare Advantage and Medicare Prescription ... Because it is approved to treat sleep apnea, Medicare covers Zepbound for that purpose. It does not cover it solely for weight loss. Patients paying the list price for the medication ...
1d
Pharmaceutical Technology on MSNGLP-1RAs show anti-cancer benefits beyond weight lossGlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate the market.
If a person has a Medicare Advantage ... cover Zepbound and other AOMs for treating obesity alone. The rules that govern Part D plans exclude “agents when used for weight loss.”
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal regulators crack down on the
The weight-loss drug revolution is reshaping the health and wellness industry, forcing companies to adapt or face the same fate as WeightWatchers, which declared bankruptcy this week. The rise in popularity of blockbuster weight-loss medications like Wegovy and Mounjaro has significantly impacted WeightWatchers' business, leading to its downfall.